QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Boston Therapeutics, Inc. (BTHE) Reports Favorable Results Of SUGARDOWN Clinical Trial 0 comments
    Jan 28, 2013 5:35 PM | about stocks: BTHE

    Boston Therapeutics today announced positive results of a clinical study of its SUGARDOWN® product, a non-systemic chewable dietary supplement tablet designed to reduce the spike in post-meal blood glucose. SUGARDOWN is designed to be taken before meals to block the action of carbohydrate-hydrolyzing enzymes, which break down carbohydrates into glucose and release them into the bloodstream.

    Conducted at the University of Sydney in Australia, the clinical trial showed that the post-meal incremental area under the curve (iAUC) for glucose and insulin were significantly lower following consumption of SUGARDOWN prior to a high carbohydrate meal of rice in a dose-dependent manner.

    SUGARDOWN was tested at two doses in 10 healthy, non-smoking subjects, resulting in a reduction of up to 61 percent in post-meal elevation of blood glucose compared with the rice consumed alone. On average, there was a 32 percent reduction in the post-meal iAUC for glucose and a 24 percent reduction in post-meal insulin.

    "These study results demonstrate that SUGARDOWN dietary supplement tablets can have a significant effect in reducing post-meal glucose and insulin responses," David Platt, Ph.D., CEO of Boston Therapeutics stated in the press release. "Such a nutritional approach may be valuable in the management of blood sugar and could enhance the role of functional dietary supplements as part of a diabetes management plan."

    Boston Therapeutics reports that no severe adverse effects were reported or observed during the study.

    For more information visit bostonti.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: BTHE
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.